Browsing by Subject "Hepatitis C virus (HCV)"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    The new standard of HCV therapy: Treatment in therapy-naive patients
    (Wiley, 2012-03-06) Agrawal, Saurabh; Kwo, Paul Y.; Medicine, School of Medicine
  • Thumbnail Image
    Item
    Spectrum of Kidney Diseases in Patients With Hepatitis C Virus Infection
    (Oxford University Press, 2021) Guo, Shunhua; Kapp, Meghan E.; Beltran, Diego M.; Cardona, Cesar Y.; Caster, Dawn J.; Reichel, Ronald R.; Fogo, Agnes B.; Pathology and Laboratory Medicine, School of Medicine
    Objectives: To study the pathologic spectrum of kidney diseases in patients with hepatitis C virus infection (HCV+). Methods: Native kidney biopsy specimens in HCV+ patients were reviewed. Results: A total of 9,836 native kidney biopsy specimens were evaluated from January 2007 to December 2016, of which 273 (2.8%) were from HCV+ patients, and of these, 115 (42.1%) had diagnoses consistent with HCV-associated glomerulonephritis (GN). Non-HCV-associated kidney diseases comprised most diagnoses (158 cases, 57.9%) including non-immune complex-mediated kidney diseases (127 cases, 46.5%) and other immune complex-mediated glomerular diseases (31 cases, 11.4%). Forty-one (40.6%) patients had HCV-associated GN among 101 HCV+ patients from 2007 to 2011 vs 74 (43.0%) patients with HCV-associated GN among 172 HCV+ patients from 2012 to 2016. HCV-associated GN showed five morphologic patterns: focal proliferative (5.2%), diffuse mesangial proliferative (50.4%), diffuse membranoproliferative (28.7%), proliferative GN with crescentic lesions (7.8%), and membranous patterns (7.8%). Conclusions: We found a spectrum of pathologic changes in renal biopsy specimens of HCV+ patients, with most having diseases unrelated to HCV infection, HCV-associated GN showing five morphologic patterns, and availability of effective HCV antiviral therapy not yet resulting in major changes in the spectrum of kidney diseases in these patients.
  • Thumbnail Image
    Item
    Up-Regulation of Hepatitis C Virus Replication and Production by Inhibition of MEK/ERK Signaling
    (PLoS, 2009) Ndjomou, Jean; Park, In-woo; Liu, Ying; Mayo, Lindsey D.; He, Johnny J.; Microbiology & Immunology, IU School of Medicine
    Background Viruses interact with and exploit the host cellular machinery for their multiplication and propagation. The MEK/ERK signaling pathway positively regulates replication of many RNA viruses. However, whether and how this signaling pathway affects hepatitis C virus (HCV) replication and production is not well understood. Methods and Results In this study, we took advantage of two well-characterized MEK/ERK inhibitors and MEK/ERK dominant negative mutants and investigated the roles of the MEK/ERK signaling pathway in HCV gene expression and replication. We showed that inhibition of MEK/ERK signaling enhanced HCV gene expression, plus- and minus-strand RNA synthesis, and virus production. In addition, we showed that this enhancement was independent of interferon-α (IFN-α) antiviral activity and did not require prior activation of the MEK/ERK signaling pathway. Furthermore, we showed that only MEK and ERK-2 but not ERK-1 was involved in HCV replication, likely through regulation of HCV RNA translation. Conclusions Taken together, these results demonstrate a negative regulatory role of the MEK/ERK signaling pathway in HCV replication and suggest a potential risk in targeting this signaling pathway to treat and prevent neoplastic transformation of HCV-infected liver cells.
  • Thumbnail Image
    Item
    Updated Clinical Guidelines on the Management of Hepatitis C Infection in Children
    (MDPI, 2024-02-16) Jarasvaraparn, Chaowapong; Hartley, Christopher; Karnsakul, Wikrom; Pediatrics, School of Medicine
    Children represent only a small proportion of those infected with the hepatitis C virus (HCV) compared to adults. Nevertheless, a substantial number of children have chronic HCV infection and are at risk of complications including cirrhosis, portal hypertension, hepatic decompensation with hepatic encephalopathy, and hepatocellular carcinoma in adulthood. The overall prevalence of the HCV in children was estimated to be 0.87% worldwide. The HCV spreads through the blood. Children born to women with chronic hepatitis C should be evaluated and tested for HCV due to the known risk of infection. The course of treatment for hepatitis C depends on the type of HCV. Currently, there are two pan-genotype HCV treatments (Glecaprevir/pibrentasvir and Sofosbuvir/velpatasvir) for children. We aim to review the updated clinical guidelines on the management of HCV infection in children, including screening, diagnosis, and long-term monitoring, as well as currently published clinical trials and ongoing research on direct acting antiviral hepatitis C treatment in children.